- Home
- PLRX vs SKYE Comparison
PLRX vs SKYE Comparison
Compare PLRX & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- SKYE
- Stock Information
- Founded
- PLRX 2015
- SKYE 2012
- Country
- PLRX United States
- SKYE United States
- Employees
- PLRX N/A
- SKYE N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- PLRX Health Care
- SKYE Health Care
- Exchange
- PLRX Nasdaq
- SKYE Nasdaq
- Market Cap
- PLRX 104.4M
- SKYE 115.9M
- IPO Year
- PLRX 2020
- SKYE N/A
- Fundamental
- Price
- PLRX $1.69
- SKYE $3.89
- Analyst Decision
- PLRX Hold
- SKYE Buy
- Analyst Count
- PLRX 10
- SKYE 6
- Target Price
- PLRX $9.79
- SKYE $16.60
- AVG Volume (30 Days)
- PLRX 1.0M
- SKYE 392.1K
- Earning Date
- PLRX 08-15-2025
- SKYE 08-07-2025
- Dividend Yield
- PLRX N/A
- SKYE N/A
- EPS Growth
- PLRX N/A
- SKYE N/A
- EPS
- PLRX N/A
- SKYE N/A
- Revenue
- PLRX N/A
- SKYE N/A
- Revenue This Year
- PLRX N/A
- SKYE N/A
- Revenue Next Year
- PLRX N/A
- SKYE N/A
- P/E Ratio
- PLRX N/A
- SKYE N/A
- Revenue Growth
- PLRX N/A
- SKYE N/A
- 52 Week Low
- PLRX $1.10
- SKYE $1.14
- 52 Week High
- PLRX $16.10
- SKYE $7.47
- Technical
- Relative Strength Index (RSI)
- PLRX 62.48
- SKYE 55.34
- Support Level
- PLRX $1.45
- SKYE $3.25
- Resistance Level
- PLRX $1.79
- SKYE $3.84
- Average True Range (ATR)
- PLRX 0.12
- SKYE 0.34
- MACD
- PLRX 0.02
- SKYE -0.06
- Stochastic Oscillator
- PLRX 74.68
- SKYE 55.65
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.